Cellmid Ltd (ASX:CDY) has been busy this week showcasing the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research in Kyoto, Japan.
The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society.
READ NOW: Cellmid steps onto world stage for hair research in Japan.
Cellmid has also just opened its first Advangen Hair Biology concept store in Tokyo.
The directors of the company are putting their own money behind the company's strategy, adding a vote of confidence in operations by buying shares on-market.
Dr David King, chairman, made a direct interest purchase of 4 million shares for $80,000, and he also holds an indirect stake of 24 million shares and a line of 4 million unlisted options.
Maria Halasz, managing director and chief executive officer, snapped up 2 million shares on-market for just over $41,000, increasing her direct stake to 6 million shares along with 12 million loan shares.
Halasz has an additional an indirect position of circa 13 million.
Dr Edward Fintan Walton, a non-executive director, picked up 500,000 shares for $11,000, increasing his direct stake to 1.3 million shares and 2 million unlisted options.
Finally, Dr Martin Cross was recently appointed to the board as a non-executive director, also purchased an indirect stake (Anna Cross) in the company buying 900,000 shares for $19,800.